{"id":"W2985753547","doi":"10.1182/blood-2019-129614","title":"Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Decitabine; Internal medicine; Medicine; Oncology; Discontinuation; Clinical endpoint; Population; Randomization; Progression-free survival; Surrogate endpoint; Phases of clinical research; Cytarabine; Adverse effect; Randomized controlled trial; Gastroenterology; Clinical trial; Leukemia; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009542277,0.001598123,0.002429773,0.0006485336,0.0004269734,0.001103963,0.0007150579,0.001443835,0.003918803],"category_scores_gemma":[0.004151311,0.0003954464,0.004856438,0.0005995153,0.001228168,0.001373226,0.0008215155,0.003892995,0.000422384],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009303932,"about_ca_system_score_gemma":0.001039144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000479605,"about_ca_topic_score_gemma":0.001409499,"domain_scores_codex":[0.9969739,0.002237863,0.0001256934,0.0002898968,0.0001572114,0.0002154258],"domain_scores_gemma":[0.9966525,0.001542135,0.0006180885,0.0002644073,0.0001287407,0.0007941199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9510361,0.004399616,0.006381465,0.0006784271,0.003574502,0.00008675912,0.0001020704,0.002108327,0.00268588,0.0001445345,0.001327309,0.02747504],"study_design_scores_gemma":[0.6690181,0.26857,0.04524901,0.000132353,0.009138856,0.0002151925,0.00009488552,0.002042225,0.002140252,0.0007131762,0.002618571,0.00006736557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845285,0.007202294,0.0008903744,0.000889753,0.0001652665,0.001434512,0.002662604,0.00004517668,0.002181581],"genre_scores_gemma":[0.9873877,0.002247792,0.001423424,0.00142396,0.0002919376,0.001823084,0.004082474,0.00004051318,0.001279158],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009542277,"threshold_uncertainty_score":0.05046499,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01945934543131652,"score_gpt":0.3314044302722122,"score_spread":0.3119450848408957,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}